The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...